Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to $277000.0.

  • Caribou Biosciences' Cash from Financing Activities rose 1352.46% to $277000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 6400.37%. This contributed to the annual value of $16.7 million for FY2024, which is 8916.12% down from last year.
  • Caribou Biosciences' Cash from Financing Activities amounted to $277000.0 in Q3 2025, which was up 1352.46% from $6000.0 recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Cash from Financing Activities registered a high of $322.7 million during Q3 2021, and its lowest value of -$43000.0 during Q4 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was $606000.0 (2021), whereas its average is $32.0 million.
  • As far as peak fluctuations go, Caribou Biosciences' Cash from Financing Activities soared by 28800982.14% in 2021, and later crashed by 13385.83% in 2023.
  • Quarter analysis of 5 years shows Caribou Biosciences' Cash from Financing Activities stood at $460000.0 in 2021, then tumbled by 72.39% to $127000.0 in 2022, then tumbled by 133.86% to -$43000.0 in 2023, then skyrocketed by 9083.72% to $3.9 million in 2024, then plummeted by 92.83% to $277000.0 in 2025.
  • Its Cash from Financing Activities stands at $277000.0 for Q3 2025, versus $6000.0 for Q2 2025 and $468000.0 for Q1 2025.